Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin 10 mg added to metformin + sulfonylurea in type 2 diabetes with inadequate glycaemic control
2011-002231-26Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin 10 mg arm with Placebo arm (2 arms). Primary endpoint: Change in HbA1c from baseline to week 24. Started Jul 2011; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-002231-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002231-26.